Stay updated on Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma
Sign up to get notified when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.

Latest updates to the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page
- Check7 days agoChange DetectedRevision: v3.6.4 was added and Revision: v3.6.3 was removed. This reflects a site-wide update to the ClinicalTrials.gov interface.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check29 days agoChange DetectedAdded the revision indicator 'Revision: v3.6.3' in the footer and removed 'Revision: v3.6.2'. This reflects a minor update to the page's metadata.SummaryDifference0.1%

- Check36 days agoChange DetectedThe page's software revision has been updated from v3.6.0 to v3.6.2, indicating a backend/frontend update. The study content and available information remain the same.SummaryDifference0.1%

- Check50 days agoChange DetectedRecruitment status 'No longer looking for participants' is displayed on the study details page, and new help/navigation sections 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study' have been added. The Intervention/Treatment header is updated, and the revision tag now shows v3.6.0, replacing the previous v3.5.5.SummaryDifference0.5%

- Check57 days agoChange DetectedThe page revision stamp was updated to v3.5.5, replacing the previous v3.5.4. This appears to be a backend or CMS update rather than a change to study information or features.SummaryDifference0.1%

- Check79 days agoChange DetectedThe revision label has been updated from v3.5.3 to v3.5.4, signaling a system update. This change does not alter the study content or its presented details.SummaryDifference0.1%

Stay in the know with updates to Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma
Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.